Bain 2026 Midyear Healthcare PE Update: $51B Across 184 Deals in H1
Global healthcare private equity deal value reached $51 billion across 184 deals in the first half of 2026, down from $61 billion but up from 173 deals in H1 2025, according to Bain’s midyear update. Q2 deal count was 99, flat year over year, after a Q1 dip to 85. Active funds rose from 331 to 415, North American buyout value increased, and provider deal value rose significantly. Bain cites AI-driven uncertainty, geopolitical conflict and private credit stress, but expects continued H2 activity supported by dry powder and pressure to return capital.
Deal value is falling while count and fund participation rise, which signals more, smaller deals and heavier competition for quality assets. Operators preparing platforms for sale should note provider assets are drawing larger checks.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.
How much did healthcare PE deal value reach in H1 2026?
Healthcare PE deal value was $51 billion across 184 deals in H1 2026, down from $61 billion in H1 2025. Deal count rose from 173.
How many funds are active in healthcare PE?
Bain reports 415 active participating funds in H1 2026, up from 331 a year earlier. Q2 deal count was 99, roughly flat versus Q2 2025.
What does Bain expect for healthcare PE in H2 2026?
Bain expects continued deal activity in H2, supported by dry powder and pressure on sponsors to return capital. It cites AI disruption, geopolitical conflict and private credit stress as sources of uncertainty.